eli lilly glp-1 pill FDA approves Lilly's new weight loss Foundayo The Food and Drug Administration

Both medications require patience

ProHealth has continued to manufacture and distribute the product as of May 2026, and the brand has operated in the supplement industry since 1988 - a track record that reflects experience navigating regulatory environments

Semaglutide carries a boxed warning for risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), and is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

J Clin Microbiol 52 , 40274029, (2014)

Women taking tirzepatide achieved substantial weight loss regardless of their menopausal stage, dropping up to 26% of their total body weight